Previous 10 | Next 10 |
Cassava Sciences press release (NASDAQ:SAVA): Q1 GAAP EPS of -$0.44 misses by $0.01. At March 31, 2022, cash and cash equivalents were $209.7 million, with no debt. A total of over 120 subjects have now been enrolled in our Phase 3 studies. Studies are being conducted in over 115 clinical tri...
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cassava Sciences (NASDAQ: SAVA ) is a small biotechnology company. It is focused on a drug, simufilam, which it believes may help treat patients with Alzheimer’s disease. SAVA stock ran up more than 1,000% at o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips After multiple neurology experts harshly criticized Cassava Sciences’ (NASDAQ : SAVA ) main thesis and the integrity of its data, I strongly recommend investors refrain from owning any shares of SAVA stock. ...
The lead drug (Nuplazid) is enjoying aggressive sales growth and thereby trumping competitors. In taking success to the next level, Acadia is expanding Nuplazid's label for schizophrenia and Alzheimer's psychosis. There is also another advanced molecule (trofinetide) that is poise...
Cassava Sciences CEO Remi Barbier on Tuesday responded to an April 18 piece in The New York Times that questioned data behind some of the company's studies for its Alzheimer's candidate simufilam. The article prompted a sell-off in the stock. In addition, the piece noted that on March 30, PLo...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors may want to keep an eye on oversold shares of Cassava Sciences (NASDAQ: SAVA ). Even with the broader market down 500 points on the day, shares of SAVA are up 5% on a volume spike to 3.48 million shares. The...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cassava Sciences, Inc. (NASDAQ: SAVA ) is a clinical stage biotech firm. The company is focused on providing treatment for Alzheimer’s, a neurodegenerative disease. Its oral medicine, Simufilam, is in Phase 3 o...
- Q&A Session at Conference on Wednesday, April 27 th at 1:30PM Eastern - AUSTIN, Texas, April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it ha...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) on behalf of Cassava stockholders. Our investigation concerns wh...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...